Standigm and Protai Collaborate for Innovative Molecular Degrader Development Using AI and Structural Proteomics
In an exciting development in the field of drug discovery, Standigm, a company known for its AI-driven drug discovery technologies, and Protai, a rising star in structural proteomics, have announced their collaboration on a groundbreaking research and development initiative. This partnership aims to design selective molecular glue degraders (MGDs), a novel class of pharmaceuticals that has the potential to target disease-causing proteins previously deemed 'undruggable'. Supported by the Korea-Israel Industrial R&D Foundation (KORIL-RDF), this initiative promises to pave new pathways in therapeutic development over the next two years.
Molecular glue degraders represent a fast-evolving segment of medicine, capable of eliminating certain harmful proteins from the body more effectively than traditional drugs. However, one of the significant hurdles in developing these treatments has been achieving selectivity. This means that while the degraders must efficiently target and eliminate the harmful proteins, they must also avoid affecting similar proteins that could lead to unintended side effects. This nuanced balance is critical in maximizing the efficacy and safety of such treatments in clinical settings.
At the heart of this collaboration is Protai’s AI-driven structural proteomics platform. This advanced technology will facilitate the understanding of glue-induced ternary complexes by merging experimental structural data with AI-enhanced structure modeling. On the other hand, Standigm will leverage its proprietary generative AI platform, dubbed STELLA-MGD, which is specifically designed for the discovery of small-molecule drugs. With this combination of resources, the teams plan to execute an iterative cycle of design, testing, and analysis that integrates AI-driven molecular generation with rigorous experimental validation.
Sang Ok Song, CEO of Standigm, expressed enthusiasm about the collaboration, emphasizing that while molecular glue degraders are capable of reaching previously inaccessible targets, their selectivity has often relied on chance. He stated, "In this program, we aim to harness Standigm's proven generative AI in the molecular-glue domain, ensuring selectivity is a product of design rather than serendipity. This collaboration embodies a significant advancement in our quest for next-generation therapeutic solutions."
Similarly, Eran Seger, CEO and Co-Founder of Protai, highlighted the symbiotic nature of this partnership. He noted how Protai’s expertise in resolving protein interactions complements Standigm’s ability to craft optimized small molecules. Together, they are set to establish a systematic approach to developing selective molecular glue degraders, potentially broadening the spectrum of disease targets that can be tackled with induced-proximity therapeutics.
This collaborative endeavor is financially backed by KORIL-RDF, alongside contributions from the Ministry of Trade, Industry and Energy (MOTIE) of South Korea and the Israel Innovation Authority. As both companies embark on this significant quest to reshape the landscape of targeted therapies, the implications for disease treatment are remarkably promising.
Founded in 2015 and based in Seoul, Standigm specializes in AI-powered drug discovery across the entire early discovery workflow. Its STELLA platform, designed for the optimization of small molecules, continues to facilitate the creation of first-in-class therapies through strategic partnerships with leading pharmaceutical companies globally.
Protai, established in 2021, focuses on extracting therapeutic benefits from induced-proximity mechanisms such as PROTACs and molecular glues, leveraging a unique AIMS™ platform that amalgamates high-throughput proteomics data with AI to craft innovative therapies. The company is committed to driving forward its proprietary asset pipeline alongside collaborative endeavors within the biopharmaceutical industry.
The intersection of AI technology with advanced drug discovery techniques marks a transformative moment in the fight against difficult diseases. The Standigm-Protai collaboration is set to not only push the boundaries of what's possible in terms of therapeutic options but also open doors to systematic drug development processes. As these companies advance their research, the biomedical community and patients alike await what new wonders this partnership will unveil in the near future.
Molecular glue degraders represent a fast-evolving segment of medicine, capable of eliminating certain harmful proteins from the body more effectively than traditional drugs. However, one of the significant hurdles in developing these treatments has been achieving selectivity. This means that while the degraders must efficiently target and eliminate the harmful proteins, they must also avoid affecting similar proteins that could lead to unintended side effects. This nuanced balance is critical in maximizing the efficacy and safety of such treatments in clinical settings.
At the heart of this collaboration is Protai’s AI-driven structural proteomics platform. This advanced technology will facilitate the understanding of glue-induced ternary complexes by merging experimental structural data with AI-enhanced structure modeling. On the other hand, Standigm will leverage its proprietary generative AI platform, dubbed STELLA-MGD, which is specifically designed for the discovery of small-molecule drugs. With this combination of resources, the teams plan to execute an iterative cycle of design, testing, and analysis that integrates AI-driven molecular generation with rigorous experimental validation.
Sang Ok Song, CEO of Standigm, expressed enthusiasm about the collaboration, emphasizing that while molecular glue degraders are capable of reaching previously inaccessible targets, their selectivity has often relied on chance. He stated, "In this program, we aim to harness Standigm's proven generative AI in the molecular-glue domain, ensuring selectivity is a product of design rather than serendipity. This collaboration embodies a significant advancement in our quest for next-generation therapeutic solutions."
Similarly, Eran Seger, CEO and Co-Founder of Protai, highlighted the symbiotic nature of this partnership. He noted how Protai’s expertise in resolving protein interactions complements Standigm’s ability to craft optimized small molecules. Together, they are set to establish a systematic approach to developing selective molecular glue degraders, potentially broadening the spectrum of disease targets that can be tackled with induced-proximity therapeutics.
This collaborative endeavor is financially backed by KORIL-RDF, alongside contributions from the Ministry of Trade, Industry and Energy (MOTIE) of South Korea and the Israel Innovation Authority. As both companies embark on this significant quest to reshape the landscape of targeted therapies, the implications for disease treatment are remarkably promising.
About Standigm
Founded in 2015 and based in Seoul, Standigm specializes in AI-powered drug discovery across the entire early discovery workflow. Its STELLA platform, designed for the optimization of small molecules, continues to facilitate the creation of first-in-class therapies through strategic partnerships with leading pharmaceutical companies globally.
About Protai
Protai, established in 2021, focuses on extracting therapeutic benefits from induced-proximity mechanisms such as PROTACs and molecular glues, leveraging a unique AIMS™ platform that amalgamates high-throughput proteomics data with AI to craft innovative therapies. The company is committed to driving forward its proprietary asset pipeline alongside collaborative endeavors within the biopharmaceutical industry.
Conclusion
The intersection of AI technology with advanced drug discovery techniques marks a transformative moment in the fight against difficult diseases. The Standigm-Protai collaboration is set to not only push the boundaries of what's possible in terms of therapeutic options but also open doors to systematic drug development processes. As these companies advance their research, the biomedical community and patients alike await what new wonders this partnership will unveil in the near future.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.